HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?


Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.


Hope S. Rugo, MD, FASCO: We don’t want to abandon our older drugs, right? I’m going to ask you 2 things. One, is there still a role for everolimus and how would you put that into your sort of schema, sequencing of treatment? And two, what do you think about the SERDs [selective estrogen receptor downregulators]? You heard about the update subsets in the EMERALD, and then 2 trials which haven’t been reported publicly have press releases saying they weren’t better than the treatment of physician choice endocrine therapy.

Anne O’Dea, MD: The first question about everolimus—it’s certainly a tool in our arsenal; it’s something that we need to remember for selected patients who for whatever reason maybe haven’t tolerated CDK4/6 or some other endocrine therapies. It’s hard to imagine now if we look at time to progression post CDK4/6 with everolimus, it’s really not very good. Therefore, it’s hard to imagine a scenario in the era of PIK3CA inhibitors and the era of antibody drug conjugates for HER2 low also in this space. It’s very hard to imagine a very large use for everolimus, although certainly I have patients who really prefer being on that oral agent for whatever reason and want to give an oral-targeted agent 1 more try before they move forward into potential intravenous therapeutic options.

Hope S. Rugo, MD, FASCO: A lot of the trials actually that are being planned, including trials with elacestrant, will have arms combined with everolimus. Elacestrant, giredestrant [ph] has one. I know Avera [ph], it’s called? There are some others, too, who don’t have a PIK3CA mutation, right? Are you still using everolimus in clinical practice?

Mark Pegram, MD: Of course, yes, at least in 2022. That’s another line of endocrine therapy. They can install the need for cytotoxic chemotherapy and its associated [adverse] effects. I wonder what’s going to happen in the ADC [antibody-drug conjugates] era. The ADC trials, though, are patient populations that have had some prior chemo already; it probably can’t replace another line of hormone therapy.

Hope S. Rugo, MD, FASCO: They’re generally better tolerated, yes. Although for some, maybe not. I don’t know for sure.

Transcript edited for clarity.

Related Videos
Judy C. Boughey, MD
Francisco J. Esteva, MD, PhD
Stephanie L. Graff, MD
Malinda West, MD
Marina Sharifi, MD, PhD
Related Content